Targeted chemo into liver for colorectal cancer spread
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial is testing a new way to give the chemotherapy drug paclitaxel directly into the liver (through a tiny tube) along with standard systemic treatment for people whose colorectal cancer has spread only to the liver and cannot be surgically removed. The goal is to see if this targeted approach works better than standard treatment alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your colorectal cancer has spread to the liver and cannot be removed by surgery.
- You have not had any chemotherapy or immunotherapy for this cancer that has spread.
- You have at least one tumor in the liver that measures 1 cm or more and has not been treated locally.
- You are in generally good health (able to take care of yourself and up and about more than half the day).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an EGFR-targeting antibody to chemotherapy can help people with colorectal cancer that has spread to the liver. It's for those whose tumors have a normal RAS gene and who have not had treatment before.
This trial tests a combination of three chemotherapy drugs (liposomal irinotecan, oxaliplatin, and capecitabine) given directly into the liver blood vessel after surgery to remove colorectal cancer that has spread to the liver. The goal is to reduce the chance of cancer coming back.
This Phase 3 trial tests different ways to deliver chemotherapy for colon cancer that has spread only to the liver (with limited possible tiny lung spots). It looks at whether the treatment plan improves outcomes compared with another chemotherapy approach, using oxaliplatin and LV5FU2 (with or without irinotecan) plus an added targeted medicine.
This trial tests whether adding two targeted drugs (serplulimab and bevacizumab) to standard chemotherapy before surgery can improve outcomes for people with colorectal cancer that has spread to the liver. It is for those whose cancer has certain genetic features and is considered resectable.
This trial tests a combination of two chemotherapy drugs (FTD and tipiracil), a targeted therapy (bevacizumab), and a radiation treatment (radioembolization) for people with colorectal cancer that has spread mainly to the liver and hasn't responded to other treatments. The goal is to see if this combination can shrink tumors and help control the cancer.
This trial tests a strong chemotherapy combination given directly into the liver's blood supply (called HAIC) for people whose colorectal cancer has spread only to the liver and cannot be removed with surgery yet. The goal is to shrink the liver tumors enough so they can be surgically removed.
Hear when a new Colorectal Liver Metastases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.